# STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

> **NCT03489629** · PHASE2 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 37 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Trimethoprim Sulfamethoxazole (TMP/SMX)
- **DRUG:** Minocycline
- **DRUG:** Mupirocin
- **DRUG:** Chlorhexidine Gluconate
- **BEHAVIORAL:** Environmental Decontamination

## Key facts

- **NCT ID:** NCT03489629
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-03
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-01-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489629, "STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03489629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*